SynthesisDigestive diseases and sciences2025
Radiation Therapy for Abdominal or Pelvic Cancer Treatment in Patients with Inflammatory Bowel Disease: A Systematic Review.
Synthesis in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Organ Preservation After Total Neoadjuvant Therapy in a Patient With Low Rectal Adenocarcinoma and Crohn's Disease.ACG case reports journal · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIBD is considered a relative contraindication to the use of radiation therapy (RT) due to risks of disease exacerbation and GI toxicity. Currently, there are limited available data on how well patients with IBD tolerate RT.
methodsAn electronic search was conducted on PubMed, Cochrane, Embase, and Medline. Eligible studies consisted of all peer-reviewed articles reporting outcomes of RT use in the treatment of abdominopelvic neoplasms in IBD patients. Evidence on RT outcomes is evaluated, namely GI toxicity and IBD activity.
resultsA total of 21 articles with 1,226 patients were identified and included. Patients were most commonly treated for prostate cancer (62%). Modes of RT included EBRT (57%), brachytherapy (33%), and stereotactic RT (9%). IBD flares within 6 months of RT ranged between 3.5% and 15%. Risk factors for flares were rectal IBD (p = 0.012) and the concomitant use of chemotherapy and RT (p = 0.02). Common low-grade GI toxicities (grade I-II) were diarrhea (32%) and proctitis (27%). Rectal bleeding ranged from 5 to 23%. Acute grade III-IV GI toxicities ranged between 5 and 23%, while late grade III-IV GI toxicities ranged between 5 and 15%. Patients with IBD receiving RT had significantly higher rates of wound dehiscence and SBO compared to patients without IBD.
conclusionRT in IBD patients can cause acute high-grade toxicity (up to 23%) and late toxicity (up to 15%). Individualized RT decisions considering IBD location and activity are essential. Prospective studies are needed to investigate flares, toxicities, and optimize RT subtypes, doses, and techniques for this population.
Indexed as
Identifiers
40526318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.